Biotechnology Stock News
Categories
- All
- Editor's Picks
- Stock Market News
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
GuruFocus Research Biotechnology
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and Strategic Advances Amid Challenges
Discover how Mirum Pharmaceuticals achieved a 137% increase in sales and navigated significant operational hurdles in the first quarter of 2024. May 09, 2024
GuruFocus Research Biotechnology
Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Market Expansion
Explore key financial outcomes and strategic insights from Tarsus Pharmaceuticals' first quarter of 2024, highlighting significant sales growth and market penetration efforts. May 09, 2024
GuruFocus Research Biotechnology
Arcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and Seizing Opportunities
Despite a widened net loss, Arcturus Therapeutics reports revenue growth and promising advancements in vaccine development. May 09, 2024
GuruFocus Research Biotechnology
Arcus Biosciences Inc (RCUS) Q1 2024 Earnings Call Transcript Highlights: Strategic Partnerships and Robust Pipeline Progress
Discover how Arcus Biosciences Inc (RCUS) leverages strong financials and strategic collaborations to advance its oncology pipeline. May 09, 2024
GuruFocus Research Biotechnology
ChromaDex Corp (CDXC) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Seizing Growth Opportunities
Despite a slight revenue dip, ChromaDex maintains a robust financial stance with strategic expansions and positive EBITDA in Q1 2024. May 09, 2024
GuruFocus Research Biotechnology
Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic Progress Amid Financial Adjustments
Explore key financial outcomes and strategic updates from Relmada Therapeutics' first quarter of 2024, emphasizing advancements in clinical trials and operational efficiencies. May 09, 2024
GuruFocus Research Biotechnology
Mind Medicine Inc (MNMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic Advances Amid Financial Volatility
Explore key financial outcomes and strategic milestones as Mind Medicine navigates increased expenses and promising clinical advancements. May 09, 2024
GuruFocus Research Biotechnology
Vanda Pharmaceuticals Inc (VNDA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and Seizing Opportunities
Amidst revenue declines and regulatory hurdles, Vanda Pharmaceuticals strategizes on new drug applications and market expansions. May 09, 2024
GuruFocus Research Biotechnology
ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue Growth and Strategic Insights
ACADIA Pharmaceuticals showcases a 74% revenue surge and strategic expansions in its Q1 2024 earnings, underlining strong sales and future market plans. May 09, 2024
GuruFocus Research Biotechnology
Aadi Bioscience Inc (AADI) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Progressing Clinical Trials
Despite a dip in FYARRO sales and increased losses, AADI advances significant clinical trials and maintains a strong cash position. May 09, 2024
GuruFocus Research Biotechnology
Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights and Financial Performance
Unveiling key financial results and strategic directions, including the impactful launch of VOWST and promising developments in SER-155. May 09, 2024
GuruFocus Research Biotechnology
Editas Medicine Inc (EDIT) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and Capitalizing on Strategic Opportunities
Despite a revenue dip, Editas Medicine strengthens its clinical trials and extends strategic partnerships, setting a robust path for future growth. May 09, 2024
GuruFocus Research Biotechnology
Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Capitalizing on Growth Opportunities
Amidst leadership changes and competitive pressures, Y-mAbs Therapeutics Inc reports robust U.S. sales growth and strategic global expansions. May 09, 2024
GuruFocus Research Biotechnology
Zevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and Capitalizing on New Opportunities
Despite a net loss, Zevra Therapeutics advances with promising drug trials and secures substantial financial flexibility through a new credit facility. May 09, 2024